Phase I
Vertex Pharmaceuticals announced positive Day 90 data from the first patient in its Phase I/II study of VX-880 in type 1 diabetes.
Cartesian’s Descartes-08 is a new chimeric antigen receptor (CAR) - T cell therapy that strives to target the myasthenia gravis disease at its source.
It was yet another busy week for clinical trial announcements. Take a look.
CT38 is being studied in myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS), as well as in fibromyalgia and chronic Lyme disease.
Less private investment and innovation in the development of new antibiotics are impeding efforts to combat drug-resistant infections.
CRISPR Therapeutics provided updated data from its ongoing Phase I CARBON trial of CTX110, its allogeneic “off-the-shelf” CAR-T therapy for CD19+ B-cell cancers.
Variety, passion and the ability to make tangible improvements in people’s lives have propelled John Fowler, co-founder and CEO of Kezar Life Sciences, throughout his career.
According to Fauci, kids can safely go trick-or-treating outdoors this Halloween. He did add that children who are eligible for COVID-19 vaccinations should do so for an “extra degree of protection.”
Pathogens for antimicrobial resistance may still be a bit off peoples’ radar, but the lessons from unpreparedness of COVID-19 are in the mind of Qpex.
Of these six patients, three had a partial response (PR) with their tumors shrinking by more than 30%.
PRESS RELEASES